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Abstract
Canada’s federal government has once again failed to shut North America’s only authorized supervised injection
facility: Insite. A majority ruling issued by the BC Court of Appeal on 15 January 2010 upheld an earlier British
Columbia Supreme Court ruling in 2008 that protected the rights of injection drug users (IDUs) to access Insite as
a health facility as per the Charter of Rights and Freedoms component of the Constitution of Canada. The majority
decision from Honourable Madam Justices Rowles, Huddart and Smith also established a jurisdictional victory safe-
guarding Insite as most appropriately run under the authority of the province of British Columbia rather than the
federal Government of Canada. The Federal Government has appealed the case to the Supreme Court of Canada.
A hearing date has been set for 12 May 2011. The appeal will be a legal one but even more so, it will be an
appeal to humanity.
Canada’s federal government has once again failed to
shut North America’s only authorized supervised injec-
tion facility: Insite. A majority ruling issued by the BC
Court of Appeal on 15 January 2010 upheld an earlier
British Columbia Supreme Court ruling in 2008 that
protected the rights of injection drug users (IDUs) to
access Insite as a health facility as per the Charter of
Rights and Freedoms component of the Constitution of
Canada.
The majority decision from Honourable Madam Jus-
tices Rowles, Huddart and Smith also established an
important jurisdictional victory emerging from the cross
appeal by the operators of Insite: the PHS Community
Services Society (PHS). The ruling further safeguards
Insite as most appropriately run under the authority of
province of British Columbia rather than the federal
Government of Canada.
Insite opened on 21 September of 2003 under an
exemption granting it status as a scientific pilot study
until 12 September 2006. The primary goals of the pro-
gram are: (1) to reach a marginalized group of IDUs with
healthcare and supports who would otherwise be forced
to use drugs in less safe settings (2) to reduce dangerous
injection practices (syringe sharing) thereby reducing the
risk of infectious diseases like HIV and HCV; and (3) to
reduce fatal overdoses in the population of people that
use the facility. The program also aims to provide refer-
rals to treatment and detoxification, reduce public disor-
der (public injection) and validate the personhood of a
deeply stigmatized target population [1].
The legal battle began near the end of Insite’s three-
year exemption for scientific study when a minority
conservative government was elected in Canada on 6
February 2006. The new government voiced opposition
to the program during and after the election [2-4]. On 1
September 2006, the program was given a temporary
extension to operate until 31 December of 2007. Before
this reprieve, the community waited in apprehension.
The photograph below (Figure 1) shows an announce-
ment of support for the supervised injection facility
from a humble church in the inner city of Vancouver
where Insite makes its home. This same church opens
its pews up each night for the homeless to sleep and
has held many services for local residents who died of
preventable overdoses before Insite was opened. [insert
figure here] For the people living with addictions and
their families who face the dangers of preventable over-
doses and infections in their everyday lives, the fate of
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risk that is lived [5].
On 2 October 2007, the project was given an additional
exemption to operate under the Controlled Drugs and
Substances Act u n t i l3 0J u n e3 02 0 0 8 .Al o o m i n gt h r e a t
of closure by the conservative led government led the
PHS to take the Government of Canada to court in late
2007 [6]. The outcome of this first legal case determined
that the Controlled Drugs and Substances Act (CDSA) in
Canada is unconstitutional as it pertains to Insite because
the closure of the program under the Act would impede
people with addictions from receiving life saving health-
care. BC Supreme Court Justice Ian Pitfield ruled that the
use of the CDSA to shut Insite would undermine the
fundamental right, under Canada’s Charter of Rights and
Freedoms to life, liberty and security of the person [7].
Since its inception, Insite has been subject to an inde-
pendent review by a team of physicians and scientists
put in place to provide an “arm’sl e n g t h ” evaluation of
the program. The results of this scientific evaluation
have been published in peer-reviewed academic journals
and have indicated that Insite has reduced unsafe injec-
tion practices, public disorder, overdose deaths and
HIV/Hepatitis while increasing uptake of addiction ser-
vices and detox [8]. To date, there have been over
three-dozen peer-reviewed papers evaluating Insite pub-
lished making it one of the most evaluated healthcare
programs in the history of Canada [9-38]. In light of the
evidence, the program has garnered widespread support
from Canadian physicians, scientists and healthcare pro-
fessionals [39].
Despite this support from the scientific and medical
community, the Conservative government of Canada
remains entrenched in its position having served the
PHS with court documents indicating their intention to
appeal the case of Insite to the highest court in the
country: the Supreme Court of Canada [40]. A court
date to hear the case has been set for 12 May 2011 by
the Supreme Court of Canada. It appears that science
and ideology are once again at odds while Canada’s
highest court is asked to determine whether the earth is
flat or round in the universe of addiction. When Insite
reaches the end of its legal journey in Canada, hopefully
the courts will once again rule that addiction is princi-
pally an issue for the Chief of Medicine rather than the
C h i e fo fP o l i c e .A sar e s u l t ,t h ec a s ei sm o r et h a na n
appeal to the Canada’s highest court; it is an appeal to
the country’s humanity.
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